

PA-IDC

QUERY CONTROL FORM				RTIS USE ONLY	
Application No.	09/507,968	Prepared by	NPB	Tracking Number	05905914
Examiner-GAU	Kemmerer-16449	Date	8/21/04	Week Date	02/16/04
		No. of queries	3	IFW (E)	

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION	MESSAGE		
	(1) Original claim 343 (now claim 198) depends from a canceled original claim 342. Please advise/correct claim dependency.		
	(2) Original claim 310 (now claim 198) is shown as allowed in the index of claim, but not shown as allowed in NOA (Notice of Allowability). Please verify if claim 310 is allowed. If so, please supply new NOA showing original claim 310 as allowed.		
	(3) Original claim 430 (now claim 129 in the index of claim) is shown as allowed in NOA and index, but missing from specification. Please advise/supply.		
	CLAIMS	RESPONSE	
		initials <i>Thompson</i>	
		initials <i>atk</i>	

192 *191*
326. The protein of claim *325* wherein said label is a radiolabel selected from the group consisting of:

- (a) ^{131}I ;
- (b) ^{125}I ;
- (c) ^{121}I ;
- (d) ^{112}In ; and
- (e) $^{99\text{m}}\text{Tc}$.

193 *188*
327. The protein of claim *324* wherein the protein is cytotoxic to Neutrokin- α receptor bearing cells.

194 *188*
328. The protein of claim *324* bound to a solid support.

195 *188*
329. A composition comprising the protein of claim *324* and a carrier.

196 *188*
340. A protein produced by a method comprising:
(a) expressing the protein of claim *324* by a cell; and
(b) recovering the protein.

197
341. (Amended) An isolated protein comprising an amino acid sequence of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA clone contained in ATCC Deposit Number 97768 wherein said protein modulates leukocyte proliferation, differentiation or survival.

342 (Cancelled)

198
343. The protein of claim 342 which comprises an amino acid sequence of at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA clone contained in ATCC Deposit Number 97768.

344. The protein of claim 341 wherein the protein modulates leukocyte proliferation.

174

~~304.~~ The protein of claim ~~290~~ bound to a solid support.

166

175
305.

A composition comprising the protein of claim ~~290~~ and a carrier.

166

176
306.

A protein produced by a method comprising:

(a) expressing the protein of claim ~~290~~ by a cell; and
(b) recovering the protein.

177

~~307.~~ (Amended) An isolated protein consisting of a first amino acid sequence that is 95% or more identical to a second amino acid sequence consisting of the amino acid sequence of an amino-terminal deletion protein mutant of the full-length protein encoded by the cDNA clone contained in ATCC Deposit Number 97768, wherein said amino-terminal deletion protein mutant excludes up to 133 amino acid residues from the amino terminus of said full-length protein encoded by the cDNA clone contained in ATCC Deposit Number 97768, and wherein said protein modulates leukocyte proliferation, differentiation or survival.

~~308.~~ The protein of claim ~~307~~ wherein the protein modulates leukocyte proliferation.

309

~~The protein of claim ~~308~~ wherein the leukocyte is a lymphocyte.~~

178

310.

The protein of claim ~~307~~ wherein the protein stimulates leukocyte

179

proliferation.

311.

~~The protein of claim ~~310~~ wherein the leukocyte is a lymphocyte.~~

Not shown
as allowed
in NOA.
please verify.

312.

The protein of claim ~~307~~ wherein the protein modulates leukocyte

differentiation.

313.

~~The protein of claim ~~312~~ wherein the leukocyte is a lymphocyte.~~

218
424. A Neutrokin-alpha multimer comprising the protein of claim 124. 70

219
425. A Neutrokin-alpha multimer comprising the protein of claim 142. 82

220
426. A Neutrokin-alpha multimer comprising the protein of claim 160. 94

221
427. A Neutrokin-alpha multimer comprising the protein of claim 178. 106

222
428. A Neutrokin-alpha multimer comprising the protein of claim 290. 166

223
429. A Neutrokin-alpha multimer comprising the protein of claim 307. 171

430. missing

Claim	Claim	Date
141	10/27/03	8/27/03
142	10/27/03	8/27/03
143	10/27/03	8/27/03
144	10/27/03	8/27/03
145	10/27/03	8/27/03
146	10/27/03	8/27/03
147	10/27/03	8/27/03
148	10/27/03	8/27/03
149	10/27/03	8/27/03
150	10/27/03	8/27/03
151	10/27/03	8/27/03
152	10/27/03	8/27/03
153	10/27/03	8/27/03
154	10/27/03	8/27/03
155	10/27/03	8/27/03
156	10/27/03	8/27/03
157	10/27/03	8/27/03
158	10/27/03	8/27/03
159	10/27/03	8/27/03
160	10/27/03	8/27/03
161	10/27/03	8/27/03
162	10/27/03	8/27/03
163	10/27/03	8/27/03
164	10/27/03	8/27/03
165	10/27/03	8/27/03
166	10/27/03	8/27/03
167	10/27/03	8/27/03
168	10/27/03	8/27/03
169	10/27/03	8/27/03
170	10/27/03	8/27/03

original
claim 310
not
allowed
M
NOA

Claim	Claim	Date
171	10/27/03	8/27/03
172	10/27/03	8/27/03
173	10/27/03	8/27/03
174	10/27/03	8/27/03
175	10/27/03	8/27/03
176	10/27/03	8/27/03
177	10/27/03	8/27/03
178	10/27/03	8/27/03
179	10/27/03	8/27/03
180	10/27/03	8/27/03
181	10/27/03	8/27/03
182	10/27/03	8/27/03
183	10/27/03	8/27/03
184	10/27/03	8/27/03
185	10/27/03	8/27/03
186	10/27/03	8/27/03
187	10/27/03	8/27/03
188	10/27/03	8/27/03
189	10/27/03	8/27/03
190	10/27/03	8/27/03
191	10/27/03	8/27/03
192	10/27/03	8/27/03
193	10/27/03	8/27/03
194	10/27/03	8/27/03
195	10/27/03	8/27/03
196	10/27/03	8/27/03
197	10/27/03	8/27/03
198	10/27/03	8/27/03
199	10/27/03	8/27/03
200	10/27/03	8/27/03
201	10/27/03	8/27/03
202	10/27/03	8/27/03
203	10/27/03	8/27/03
204	10/27/03	8/27/03
205	10/27/03	8/27/03
206	10/27/03	8/27/03
207	10/27/03	8/27/03
208	10/27/03	8/27/03
209	10/27/03	8/27/03
210	10/27/03	8/27/03

Claim	1	2	3	4	Date
198	✓	✓	✓	✓	
199	✓	✓	✓	✓	
200	✓	✓	✓	✓	
201	✓	✓	✓	✓	
202	✓	✓	✓	✓	
203	✓	✓	✓	✓	
204	✓	✓	✓	✓	
205	✓	✓	✓	✓	
206	✓	✓	✓	✓	
207	✓	✓	✓	✓	
208	✓	✓	✓	✓	
209	✓	✓	✓	✓	
210	✓	✓	✓	✓	
211	✓	✓	✓	✓	
212	✓	✓	✓	✓	
213	✓	✓	✓	✓	
214	✓	✓	✓	✓	

Claim	Unit	Original	8	10	23	17	10
15	429	✓					
	151						
	153						
	155						
	156						
	156		=				
	157						
	158						
	159						
160	440		=				
	161						
	162						
	163						
	164		=				
	165						
	166						
	167						
	168						
	169						
	170						
	171						
	172						
	173						
	174		=				
	175						
	176						
	177						
	178						
	179	✓					
180	450		=				
	181						
	182						
	183						
	184						
	185						
	186						
	187						
	188						
	189						
	190						
	191						
	192						
	193						
	194						
	195						
	196						
	197						
	198						
	199						
	200						

Notice of Allowability	Application No.	Applicant(s)
	09/507,968 Examiner Bridget E. Bunner	YU ET AL. Art Unit 1647

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address—
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to the amendment of 16 July 2003.
2. The allowed claim(s) is/are 26-29, 31-41, 44-45, 48-61, 70-81, 83-86, 89, 93, 95-107, 116-125, 128, 132, 134-143, 146, 150, 152-161, 164, 168, 170-180, 186, 188-196, 205-213, 215, 225-231, 247-251, 260-273, 276, 280 and 282-290, 293, 297, 299-307, 314, 316-324, 333-341, 343, 352-359, 362, 366, 370, 374, 378, 382, 386, 390, 406, 410, 414, 424-430.
3. The drawings filed on 14 August 2001 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - (a) The translation of the foreign language provisional application has been received.
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE

7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. CORRECTED DRAWINGS must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No. _____.
 - (b) Including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.

9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

<input type="checkbox"/> Notice of References Cited (PTO-892)	<input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
<input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	<input type="checkbox"/> Interview Summary (PTO-413), Paper No. _____.
<input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449), Paper No. <u>25</u> .	<input checked="" type="checkbox"/> Examiner's Amendment/Comment
<input checked="" type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	<input type="checkbox"/> Examiner's Statement of Reasons for Allowance
	<input type="checkbox"/> Other

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.